OBJECTIVE: The brain is one of the main targets of hypertension. However, little is known about the relation between hypertension and motor performances. We studied the association between hypertension and walking speed in a cohort of elderly people. METHODS: Analyses are based on participants (65-85 years) from the Dijon (France) center of the Three-City study (n = 3604), followed every 2 years. Persistent hypertension was defined by the use of antihypertensive drugs at baseline or at first follow-up, or by high blood pressure (> or =140/90 mmHg) at baseline and first follow-up. Walking speed was measured over 6 m, at baseline and fourth follow-up (n = 1774) after a mean (SD) duration of 7.0 (0.5) years. Brain MRI was performed in 1590 participants. Generalized linear models were used to assess the relation between hypertension and baseline walking speed or walking speed change. RESULTS: At baseline, mean (SD) walking speed (m/s) was lower in hypertensive patients [1.51 (0.31)] than in nonhypertensive individuals [1.59 (0.30), P < 0.001]. During follow-up, hypertensive patients had a higher mean annual decline in walking speed [cm/s per year; 2.30 (3.4)] than nonhypertensive individuals [1.87 (3.3), P = 0.004]. The number of antihypertensive drugs was associated with lower walking speed at baseline and higher walking speed decline. Adjustment for MRI white matter abnormalities attenuated these relations. CONCLUSION: Persistent hypertension was associated with both lower walking speed and higher decline in walking speed in the elderly. These results may be partly explained by white matter abnormalities and support the hypothesis of a contribution of vascular risk factors to motor dysfunction.
OBJECTIVE: The brain is one of the main targets of hypertension. However, little is known about the relation between hypertension and motor performances. We studied the association between hypertension and walking speed in a cohort of elderly people. METHODS: Analyses are based on participants (65-85 years) from the Dijon (France) center of the Three-City study (n = 3604), followed every 2 years. Persistent hypertension was defined by the use of antihypertensive drugs at baseline or at first follow-up, or by high blood pressure (> or =140/90 mmHg) at baseline and first follow-up. Walking speed was measured over 6 m, at baseline and fourth follow-up (n = 1774) after a mean (SD) duration of 7.0 (0.5) years. Brain MRI was performed in 1590 participants. Generalized linear models were used to assess the relation between hypertension and baseline walking speed or walking speed change. RESULTS: At baseline, mean (SD) walking speed (m/s) was lower in hypertensivepatients [1.51 (0.31)] than in nonhypertensive individuals [1.59 (0.30), P < 0.001]. During follow-up, hypertensivepatients had a higher mean annual decline in walking speed [cm/s per year; 2.30 (3.4)] than nonhypertensive individuals [1.87 (3.3), P = 0.004]. The number of antihypertensive drugs was associated with lower walking speed at baseline and higher walking speed decline. Adjustment for MRI white matter abnormalities attenuated these relations. CONCLUSION: Persistent hypertension was associated with both lower walking speed and higher decline in walking speed in the elderly. These results may be partly explained by white matter abnormalities and support the hypothesis of a contribution of vascular risk factors to motor dysfunction.
Authors: B W Penninx; L Ferrucci; S G Leveille; T Rantanen; M Pahor; J M Guralnik Journal: J Gerontol A Biol Sci Med Sci Date: 2000-11 Impact factor: 6.053
Authors: Javed Butler; Ghazanfar Khadim; Rhonda Belue; Don Chomsky; Robert S Dittus; Marie Griffin; John R Wilson Journal: J Card Fail Date: 2003-06 Impact factor: 5.712
Authors: H Baezner; C Blahak; A Poggesi; L Pantoni; D Inzitari; H Chabriat; T Erkinjuntti; F Fazekas; J M Ferro; P Langhorne; J O'Brien; P Scheltens; M C Visser; L O Wahlund; G Waldemar; A Wallin; M G Hennerici Journal: Neurology Date: 2008-03-18 Impact factor: 9.910
Authors: Patricia M Kearney; Megan Whelton; Kristi Reynolds; Paul Muntner; Paul K Whelton; Jiang He Journal: Lancet Date: 2005 Jan 15-21 Impact factor: 79.321
Authors: Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler Journal: N Engl J Med Date: 2003-03-27 Impact factor: 91.245
Authors: Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella Journal: Hypertension Date: 2003-12-01 Impact factor: 10.190
Authors: Aileen P McGinn; Robert C Kaplan; Joe Verghese; Daniel M Rosenbaum; Bruce M Psaty; Alison E Baird; John K Lynch; Philip A Wolf; Charles Kooperberg; Joseph C Larson; Sylvia Wassertheil-Smoller Journal: Stroke Date: 2008-02-21 Impact factor: 7.914
Authors: Ewoud J van Dijk; Monique M B Breteler; Reinhold Schmidt; Klaus Berger; Lars-Göran Nilsson; Matthijs Oudkerk; Andrzej Pajak; Susana Sans; Maria de Ridder; Carole Dufouil; Rebecca Fuhrer; Simona Giampaoli; Lenore J Launer; Albert Hofman Journal: Hypertension Date: 2004-10-04 Impact factor: 10.190
Authors: Thomas W Buford; Todd M Manini; Fang-Chi Hsu; Matteo Cesari; Stephen D Anton; Susan Nayfield; Randall S Stafford; Timothy S Church; Marco Pahor; Christy S Carter Journal: J Am Geriatr Soc Date: 2012-06-21 Impact factor: 5.562